Skip to main content

Table 3 Prevalence of malaria according to selected risk factors among HIV infected pregnant women receiving co-trimoxazole (N = 420)

From: Prevalence of malaria and anaemia among HIV infected pregnant women receiving co-trimoxazole prophylaxis in Tanzania: a cross sectional study in Kinondoni Municipality

Characteristics N Malaria prevalence n (%) P-value AOR 95% CI P-value
WHO clinical stage       
Stage I 338 12 (3.6)   1   
Stage II 43 2 (4.7)   0.851 0.171-4.226 0.844
Stage III-IV 39 5 (12.8) 0.031a 2.305 0.699-7.597 0.170
CD4 count (cells/μL)*       
≥500 104 4 (3.8)   -   
350-499 85 3 (3.5)   -   
200-349 96 8 (8.3)     
<200 59 4 (6.8) 0.417a -   
Pregnancy trimester       
1st trimester 20 1 (5)   -   
2nd trimester 206 9 (4.4)   -   
3rd trimester 194 9 (4.6) 0.986a -   
Gravidity       
Primigravidae 139 6 (4.3)   -   
Secundigravidae 148 5 (3.4)   -   
Multigravidae 133 8 (6) 0.563a -   
Adherence to co-trimoxazole       
Good 208 2 (1)   1   
Average 80 4 (5)   3.578 0.611-20.955 0.157
Poor 132 13 (9.8) 0.001a 6.806 1.346-34.429 0.02
ITN use       
Yes 380 15 (3.9)   -   
No 40 4 (10) 0.096b -   
ART use category       
Prophylaxis 288 11 (3.8)   -   
Life long 132 8 (6.1) 0.305a -   
  1. aCalculated by Pearson Chi Square, bCalculated by Fischer’s Exact Test, *Results of CD4 count were available for only 344 subjects out of 420 (81.9%).
\